A Study Of Inotuzumab Ozogamicin Plus Rituximab For Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma Patients Who Are Not Candidates For Intensive High-Dose Chemotherapy

Stopped The study was terminated prematurely on May 16, 2013, for futility. No new or unexpected safety issues were identified.

Conditions

• Lymphoma, Non-Hodgkin

Interventions

• DRUG: Inotuzumab ozogamicin
• DRUG: Rituximab
• DRUG: rituximab + gemcitabine
• DRUG: rituximab +bendamustine

Sponsor

Pfizer

Collaborators

• [object Object]